Skip to main content

Advertisement

Candidate targets for antibody therapy of rheumatoid arthritis: CD64 and IL-15

Article metrics

  • 910 Accesses

At present, blockade of cytokines represents one approach to treat rheumatoid arthritis (RA). Anti-tumor necrosis factor (TNF)-α therapy results in impressive protection against joint inflammation and joint damage in RA patients, although a significant number of patients do not respond. We evaluated blockade of targets more upstream in the inflammation cascade, of activated macrophages and of IL-15.

Inflammatory macrophages exhibit enhanced expression of FcγRI (CD64), the high-affinity receptor for IgG. We observed the presence of CD64 on activated macrophages in RA patients, and their in vitro elimination using a CD64-targed immunotoxin. In addition, we demonstrated in vivo elimination of CD64-expressing activated macrophages, resulting in significant inhibition of disease activity in an adjuvant arthritis model, in newly generated human CD64 transgenic rats. IL-15 triggers inflammatory cell recruitment, angiogenesis and production of other inflammatory cytokines, including IFN-γ, TNF-α and IL-17, which are all upregulated in inflammation. We generated monoclonal antibodies using human immunoglobulin-transgenic mice. One of the IL-15-specific antibodies, HuMax IL-15, did not compete with IL-15 for binding to its receptor, but potently interfered with the assembly of the IL-15 receptor α,β,γ complex. This antibody blocked IL-15-induced T-cell proliferation, and monocyte TNF-α release in vitro. HuMax IL-15 effectively inhibited inflammation in SCID-RA models and is currently clinically evaluated in human RA.

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

van de Winkel, J. Candidate targets for antibody therapy of rheumatoid arthritis: CD64 and IL-15. Arthritis Res Ther 5, 42 (2003) doi:10.1186/ar843

Download citation

Keywords

  • Rheumatoid Arthritis
  • Rheumatoid Arthritis Patient
  • Human CD64
  • Joint Damage
  • Joint Inflammation